大型抑郁症下躁狂症状:预后影响和治疗问题
Paolo Olgiati1, Siegfried Kasper2, Joseph Zohar3
1Department of Sciences of Public Health and Paediatrics, University of Turin, Turin, Italy; Department of Psychiatry ASLTO4, Turin, Italy.
Journal of affective disorders
|October 24, 2024
概括
大型抑郁症 (MDD) 中的躁狂症状与治疗反应较差和持续的自杀念头有关. 评估这些症状对于在具有挑战性的抑郁症病例中有效选择治疗至关重要.
科学领域:
- 精神病学是一个精神病学.
- 临床心理学 临床心理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 混合抑郁症 (MXD) 涉及主要抑郁症期间的 (低) 躁狂症状,在双相和单相情感障碍中很常见.
- MXD的预后和治疗影响仍然不清楚.
- 这项研究调查了低躁狂症状,治疗反应和自杀念头缓解之间的联系.
研究的目的:
- 检查患有严重抑郁症 (MDD) 的成年人中低躁狂症状和治疗结果之间的关系.
- 为了确定低躁狂症状是否预测治疗反应和自杀念头的缓解.
- 探索特定药物在管理MDD中低躁狂症状和自杀念头方面的作用.
主要方法:
- 从自然主义研究中对1243名患有MDD的成年人进行分析,研究治疗耐药抑郁症.
- 通过结构化访谈和临床评分表 (YMRS,MADRS) 进行横截面和回顾性数据收集.
- 单变量和多变量统计分析,以评估变量之间的关系.
主要成果:
- 在45%的患者中出现了躁狂症状;25%的患者对治疗有反应.
- 较低的低躁狂症状得分 (YMRS) 与更好的治疗反应和自杀念头的缓解相关.
- 抑郁症状负面预测治疗反应;双极谱标记物预测自杀想法缓解. 多巴胺/血清激素对抗剂改善了自杀倾向,情绪稳定剂减少了躁狂.
结论:
- 在单极性抑郁症中,躁狂症状是普遍存在的,并且与较差的结果有关.
- 对低躁狂症状的评估对于识别难以治疗的MDD病例至关重要.
- 有针对性的药理学策略,包括情绪稳定剂和特定对抗剂,可能会改善结果.
相关概念视频
01:24Mania and Antimanic Drugs: Overview
136
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
136
01:30Bipolar Disorder
56
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
56
01:27Depressive Disorders: MDD and Dysthymia
61
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
61
01:23Antidepressant Drugs: MAOIs and Other Agents
196
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
196
01:28Psychosis and Antipsychotic Drugs: Overview
183
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
183
01:26Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104